Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664979 | 1.00 | ACE (0.42) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL206311 | 1.00 | ACE (0.42) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL3710017 | 0.93 | CNR2 (0.40) | ACE | |
| SCHEMBL2223045 | 0.93 | ACE (0.43) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL124448 | 0.93 | ACE (0.37) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL3710986 | 0.93 | CNR2 (0.40) | ACE | |
| SCHEMBL9107688 | 0.93 | ACE (0.41) | ACEREN | |
| SCHEMBL1952767 | 0.93 | ACE (0.41) | ACEREN | |
| SCHEMBL28152243 | 0.93 | ACE (0.43) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL28152132 | 0.93 | ACE (0.43) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-114736151-B | Preparation method of Pa Luo Weide key intermediate and structural formula of compound | 湖南复瑞生物医药技术有限责任公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115636866-A | Method for synthesizing bridged ring compound and intermediate thereof | 南京药坦生物科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| CN-114736151-A | Preparation method of parefovir dipivoxil key intermediate and structural formula of compound | 湖南复瑞生物医药技术有限责任公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114591299-A | Paroviride intermediate and preparation and application thereof | 雅本化学股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114031543-A | Preparation method of intermediate of palovaried | 上海朴颐化学科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-2814798-B1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-8030495-B2 | Cyclopropyl pyrrolidine orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2011-10-04 | — | — | US | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-06-17 | — | — | US | disclosed |
| EP-2150115-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | Merck and Co., Inc. (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008150364-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ACE 964/4885REN 232/4885LMNA 42/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ACE 964/4885REN 232/4885LMNA 42/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ACE 964/4885REN 232/4885LMNA 42/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ACE 3990/4885REN 3530/4885LMNA 4696/4885 |
| US-20100152191-A1 | CYCLOPROPYL PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, OXTR | ACE 1258/4885REN 462/4885LMNA 3679/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ACE 964/4885REN 232/4885LMNA 42/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ACE 964/4885REN 232/4885LMNA 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.